Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of Orally Administered SP01A for 28 Days as Monotherapy Treatment in HIV-Infected Patients With Evidence of Resistance to Currently Available Antiretroviral Therapy

NCT00299897 is registered in ClinicalTrials.gov with Samaritan Pharmaceuticals, Inc as lead sponsor.

NCT NCT00299897
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00299897 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of Orally Administered SP01A for 28 Days as Monotherapy Treatment in HIV-Infected Patients With Evidence of Resistance to Currently Available Antiretroviral Therapy
Lead sponsor
Samaritan Pharmaceuticals, Inc
Phase
Phase 2
Overall status
Unknown status
Start date
March 31, 2006
Completion date
Not reported
Enrollment
60
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections, human immunodeficiency virus